
    
      The Portico NG Approval study will be conducted as a prospective, multi-center,
      international, single-arm investigational study.

      Up to 189 (includes up to 20 roll-ins) high or extreme risk patients with symptomatic, severe
      native aortic stenosis who are determined by an independent subject selection committee to
      meet eligibility criteria for Portico NG Transcatheter Aortic Heart Valve implantation will
      undergo Porticoâ„¢ NG Valve implantation via a transfemoral or alternative access approach
      according to the site's anesthesia protocol for TAVR (transcatheter aortic valve replacement)
      procedure.

      Subjects participating in the clinical study will be followed for a total of 12 months with
      data collected at screening, baseline, procedure, prior to hospital discharge, and follow-up
      at 30 days, 12 months and annually at 2, 3, 4 and 5 years.
    
  